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OBJECTIVES This study was designed to assess the diagnostic performance of B-type natriuretic peptide
(BNP) in the diagnosis of acute congestive heart failure (CHF) in patients with permanent/
paroxysmal atrial fibrillation (AF) presenting with acute dyspnea.
BACKGROUND It is unknown to what extent AF affects the diagnostic performance of BNP in patients
presenting with acute dyspnea.
METHODS We studied 1,431 patients drawn from a cohort of patients (n  1,586) with acute dyspnea
who had BNP levels measured on arrival. Patients were prospectively classified according to
the presence or absence of permanent/paroxysmal AF.
RESULTS In total, 292 patients had permanent/paroxysmal AF. In patients without HF, permanent/
paroxysmal AF was associated with significantly higher BNP levels (p  0.001). Conversely,
in patients with HF, BNP levels did not differ significantly between patients with and without
AF (p  0.533). A BNP cutoff value of 100 pg/ml had a specificity of 40% and 79% for the
diagnosis of acute HF in patients with and without AF, respectively. The areas under the
receiver-operating characteristic curves were 0.84 (95% confidence interval 0.78 to 0.89) and
0.91 (95% confidence interval 0.89 to 0.93) for patients with and without AF, respectively.
CONCLUSIONS In patients without, but not in those with HF, the presence of AF is associated with higher circulating
BNP levels, suggesting that a higher diagnostic threshold should be used in patients with AF. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.057Coll Cardiol 2005;46:838–44) © 2005 by the American College of Cardiology Foundation
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P-type natriuretic peptide (BNP) is a peptide hormone
erived from atrial and ventricular cardiomyocytes (1–4).
irculating levels of BNP are increased in conditions
haracterized by volume overload, including cardiac (3–8)
nd renal failure (9,10). The BNP levels are also increased in
atients with atrial fibrillation (AF) (11), even after con-
rolling for demographic and clinical variables (12). The
NP levels appear to decrease after successful cardioversion
o sinus rhythm (13–15).
From the *Ullevål University Hospital, Oslo, Norway; †Akershus University
ospital, University of Oslo, Oslo, Norway; ‡University of California, San Diego,
eterans Affairs Medical Center, San Diego, California; §University of California,
an Francisco, San Francisco General Hospital, San Francisco, California; Hopital
ichat, Paris, France; ¶Henry Ford Hospital, Detroit, Michigan; #University of
ennsylvania, Philadelphia, Pennsylvania; **University of Cincinnati College of
edicine, Cincinnati, Ohio; ††University of Kentucky College of Medicine, Lex-
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anufacturer of the BNP assay used in the study. Dr. Marc Silver served as Guest
ditor for this article.r
Manuscript received March 1, 2005; revised manuscript received May 6, 2005,
ccepted May 9, 2005.Currently, the principal clinical indication for BNP mea-
urement is to diagnose heart failure (HF) in patients
resenting with acute dyspnea. Using a commercially avail-
ble, automated point-of-care device and a single prespeci-
ed cutoff of 100 pg/ml, we recently documented that
easurement of BNP on admission provides valuable diag-
ostic information in this patient group (16), complementary
nd superior to clinical evaluation (17). Atrial fibrillation is not
ncommon in patients presenting with acute dyspnea, but it is
ot known whether permanent/paroxysmal AF significantly
ffects circulating levels of BNP in dyspneic patients with and
ithout HF. Moreover, it is unknown whether permanent/
aroxysmal AF affects the diagnostic performance of BNP in
his setting and whether the conventional cutoff of 100 pg/ml
rovides optimal discrimination in patients with AF. To
ddress these issues, we compared circulating levels and diag-
ostic performance of BNP in patients with and without AF in
he Breathing Not Properly cohort.
ETHODS
atients. The Breathing Not Properly Multinational Study
ecruited patients from seven centers (5 U.S. and 2 Euro-
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September 6, 2005:838–44 BNP and AFean teaching hospitals) from June 1999 to December 2000.
n all, 1,586 patients were included. The inclusion criterion
as a main complaint of dyspnea, and both patients with
cute dyspnea of sudden onset and with worsening of
hronic dyspnea were included. Patients with renal failure
calculated creatinine clearance 15 ml/min and those
eceiving dialysis therapy), acute myocardial infarction, age
elow 18 years, those who were unable to give informed
onsent, and patients whose dyspnea was clearly due to
easons other than acute HF (i.e., penetrating lung injury)
ere excluded from the study. The study design details and
ain results of the Breathing Not Properly Multinational
tudy have been published elsewhere (16). To determine
he influence of the presence of permanent/paroxysmal AF
n the diagnostic precision of BNP in the diagnosis of acute
F, this study encompasses patients in whom we had
omplete data with regard to the presence or absence of AF
n  1,431). Patients were classified according to perma-
ent/paroxysmal AF and those without AF. The perma-
ent/paroxysmal AF group of patients consists of the
ollowing patient subgroups: 1) patients with a medical
istory of AF and AF on the electrocardiogram (ECG) on
dmission (defined as permanent AF); 2) patients with a
edical history of AF, but sinus rhythm on the ECG on
dmission (defined as paroxysmal AF); and 3) patients
ithout a medical history of AF, but AF on the ECG on
dmission (defined as paroxysmal AF). The study conforms
o the principles outlined in the Declaration of Helsinki,
nd the study protocol was approved by the institutional
eview boards of all participating hospitals. Written in-
ormed consent was obtained from all participants.
ata collection. Research personnel in the emergency
epartment (ED) collected baseline demographics, medical
istory, current clinical status, and blood test results for each
atient. Electrocardiograms were interpreted by the attend-
ng ED physician and the following variables were recorded:
igns of previous myocardial infarction, ST-segment devia-
ion, left and right bundle branch block, and AF and QRS
omplex duration. The chest radiographs were evaluated by
ertified radiologists. Medical history, clinical findings,
lood test results (except for BNP), ECG findings, and
hest radiograph results were reported in a case report form
ompleted by trained research personnel in collaboration
ith the attending physicians. It was the responsibility of
he attending physicians to ensure that the case report form
Abbreviations and Acronyms
AF  atrial fibrillation
BNP  B-type natriuretic peptide
CHF  congestive heart failure
ECG  electrocardiogram/electrocardiographic
ED  emergency department
HF  heart failure
ROC  receiver-operating characteristicas in agreement with the clinical record. The attending fD physicians were, in general, certified cardiologists or
enior staff emergency medicine physicians. The ED phy-
ician and radiologist were blind to the BNP level.
lood sampling. As soon as possible following admission,
ml of blood from each patient was collected into ethyl-
nediaminetetraacetic acid tubes and the BNP concentra-
ion was measured using the Triage BNP test (Biosite
iagnostics Inc., San Diego, California). Precision, analyt-
cal sensitivity, and stability characteristics of the system
ave been described previously (18,19). The BNP tests were
un in triplicate, and final results were reported as the mean
f the three samples.
eference standard definition for the diagnosis of
F. Approximately 30 days after the ED visit, two cardi-
logists at each study center reviewed the case report form
rom the ED; ECG; chest radiograph; echocardiogram (if
erformed); and all other clinical tests, consultations, and
hart information for each patient, except for the BNP
alue. On the basis of this information, the two cardiologists
ategorized all patients in one of the following categories: 1)
yspnea due to acute HF; 2) known chronic HF, but current
yspnea due to other reason; and 3) dyspnea due to a reason
ther than acute HF. For further statistical analyses, the
atter two groups were pooled.
tatistical analysis. SPSS for Windows version 11.0
SPSS Inc., Chicago, Illinois) was used for all statistical
nalyses. Baseline characteristics are reported in percent or
edian and interquartile range. Univariate comparisons
ere made with chi-square tests for categorical variables and
ith Mann-Whitney U tests for continuous variables. A
wo-sided p value 0.05 was considered significant.
For the evaluation of diagnostic precision of BNP in
atients with and without AF, patients were divided into
wo groups: patients with permanent/paroxysmal AF and
atients without AF. Sensitivity, specificity, accuracy, pos-
tive and negative predictive values, and positive and nega-
ive likelihood ratios for the detection of acute HF were
alculated for BNP in both groups by use of different cutoff
alues (50, 100, 200, 300, 400, 500, 600, 700, and 800
g/ml). Accuracy is the degree to which the diagnostic
ecision agrees the true value of the diagnosis—in this case,
he proportion of correct diagnoses (true positives  true
egatives)/(true positives  false positives  true negatives
false negatives). As with all diagnostic statistics, this
ssumes the adjudicated diagnosis is correct. Accuracy
hanges with prevalence unless sensitivity and specificity are
qual. Median BNP value and interquartile range were
alculated in patients with permanent/paroxysmal AF with
nd without acute HF and in patients without AF with and
ithout acute HF. The independent diagnostic value of
ermanent/paroxysmal AF in patients without a final diag-
osis of HF with regard to an elevated BNP level (100
g/ml) was assessed in a multivariate logistic model for all
ariables that proved to be significant by univariate analysis
n patients with and without a final diagnosis of HF. The
ollowing dichotomous variables were evaluated in the
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BNP and AF September 6, 2005:838–44ultivariate model: medical history of CHF, myocardial
nfarction and hypertension, clinical signs of jugular vein
istension, orthopnea, lower extremity edema and rales, use
f digoxin and diuretics, QRS duration on the ECG, and
stimated creatinine clearance.
To obtain an index of overall diagnostic performance of
NP in patients with and without AF, receiver-operating
haracteristic (ROC) curves were generated and the area
nder the curve calculated. On the basis of the ROC curves,
ptimal diagnostic cutoff values for the diagnosis of acute
F were obtained in patients both with and without AF.
ESULTS
he current analysis includes 1,431 patients who all pre-
ented with a main complaint of dyspnea. Table 1 summa-
izes the characteristics of the total number of patients,
ubdivided according to the presence or absence of AF. Of
he 292 patients with permanent/paroxysmal AF, 256 pa-
able 1. Patient Characteristics
Permanent/
Paroxysmal
Atrial
Fibrillation
No Atrial
Fibrillation p Value
otal number
Patients 292 1,139
emographics
Age (yrs) 77 (67–82) 62 (49–74) 0.001
Gender (female) 113 (38.7) 502 (44.1) 0.097
edical history
Congestive heart failure 136 (46.6) 344 (30.2) 0.001
Myocardial infarction 94 (32.2) 259 (22.7) 0.001
Aterial hypertension 165 (56.5) 634 (55.7) 0.116
Diabetes mellitus 74 (25.3) 251 (22.0) 0.039
linical findings
Jugular vein distension 122 (41.8) 215 (18.9) 0.001
Orthopnea 172 (58.9) 633 (55.6) 0.305
Lower extremity edema 178 (61.0) 397 (34.9) 0.001
Rales 186 (63.7) 446 (39.2) 0.001
Body mass index (kg/m2) 25.7 (22–31) 27.4 (23–33) 0.006
edication at home
ACE inhibitors 117 (40.1) 322 (28.3) 0.001
Beta-blockers 74 (25.3) 230 (20.2) 0.042
Calcium channel blockers 87 (29.8) 208 (18.3) 0.001
Digoxin 128 (43.8) 131 (11.5) 0.001
Other antiarrhythmics 47 (16.1) 44 (3.9) 0.001
Diuretics 184 (63.0) 475 (41.7) 0.001
CG
Atrial fibrillation 158 (54.1) 0 0.001
Left bundle branch block 27 (9.2) 58 (5.1) 0.011
Right bundle branch
block
29 (9.9) 54 (4.7) 0.001
QRS duration (ms) 100 (86–128) 90 (80–104) 0.001
lood values
Creatinine clearance 51 (34–72) 65 (43–90) 0.001
BNP 100 pg/ml 251 (86.0) 541 (47.5) 0.001
BNP (pg/ml) 421 (168–911) 82 (18–506) 0.001
inal diagnosis
Acute heart failure 219 (75.0) 445 (39.1) 0.001
CE  angiotensin-converting enzyme; BNP  B-type natriuretic peptide; ECG 
lectrocardiogram.ients had a medical history of AF. Of this population, 122
5
patients presented with ECG-documented AF in the ED.
hirty-six patients who had no previous history of AF
resented with AF on the ECG at the current admission.
he patients with permanent/paroxysmal AF were signifi-
antly older than patients without AF (p  0.0001) and
hey were more likely to have a medical history of CHF,
yocardial infarction (p  0.0001 for both), and diabetes
p 0.039). Jugular vein distension, lower extremity edema,
nd rales (p  0.0001 for all) were significantly more
ommon among patients with permanent/paroxysmal AF,
s well as use of angiotensin-converting enzyme inhibitors
p  0.0001), beta-blockers (p  0.042), calcium-channel
lockers, digoxin, other antiarrhythmics, and diuretics (p 
.0001 for all). A final diagnosis of acute HF was signifi-
antly more common in the AF group of patients than in
he group of patients without AF (p  0.0001).
Circulating BNP levels were significantly higher in pa-
ients with permanent/paroxysmal AF compared to those
ithout AF: 421 (interquartile range 168 to 911) pg/ml
ersus 82 (interquartile range 18 to 506) pg/ml (p 
.0001). Circulating BNP levels in patients with/without
F and with/without a final diagnosis of acute HF are
epicted in Figure 1. In patients without HF, the BNP
alues in patients with permanent/paroxysmal AF were
ignificantly higher than in those without AF (p  0.0001).
onversely, in patients with HF, the BNP values did not
iffer significantly between patients with or without AF (p
0.811). In patients without a final diagnosis of HF, AF
odds ratio 3.2, 95% confidence interval 1.3 to 8.1) re-
ained an independent predictor of elevated BNP levels
100 pg/ml) after adjustment for medical history of CHF,
yocardial infarction and hypertension, clinical signs of
ugular vein distension, orthopnea, lower extremity edema
nd rales, use of digoxin and diuretics, QRS duration on the
CG, and estimated creatinine clearance. Characteristics of
igure 1. B-type natriuretic peptide (BNP) levels in patients with and
ithout atrial fibrillation and with and without a final diagnosis of acute
eart failure. In patients without heart failure, BNP levels were significantly
igher in patients with atrial fibrillation than in those without (p 0.001).
n patients with heart failure, BNP levels were not significantly different
etween patients with and without atrial fibrillation. B-type natriuretic
eptide levels are plotted on a log scale. The boxes represent the 25th,
0th, and 75th percentiles, and the whiskers indicate the 10th and 90th
ercentiles.
p
i
2
l
t
m
a
C
t
w
B
t
p
v
t
c
v
g
p
a
d
R
0
t
p
T
c
c
o
i
d
v
[
r
D
O
H
c
p
d
i
w
Tabl
841JACC Vol. 46, No. 5, 2005 Knudsen et al.
September 6, 2005:838–44 BNP and AFatients with permanent/paroxysmal AF subdivided accord-
ng to a final diagnosis of acute HF are summarized in Table
. Patients with a final diagnosis of acute HF were more
ikely to have a medical history of CHF, myocardial infarc-
ion and hypertension, clinical signs compatible with HF,
edication with digoxin and diuretics, and decreased cre-
tinine clearance than patients without a final diagnosis of
HF. Median BNP value was 569 (interquartile range 290
o 1,031) and 119 (interquartile range 69 to 244) in patients
ith and without HF, respectively.
Diagnostic performance for different cutoff values for
NP in the diagnosis of acute HF subdivided according to
he presence or absence of AF are presented in Table 3. In
atients with permanent/paroxysmal AF, a BNP cutoff
alue of 100 pg/ml had a specificity of only 40%, whereas
he sensitivity was 95%. Not surprisingly, specificity in-
reased and sensitivity decreased with increasing BNP cutoff
alues in both patient groups. The highest accuracy in both
roups of patients was achieved at a BNP cutoff value of 200
g/ml: 82.2 for patients with permanent/paroxysmal AF
nd 84.5 for patients without AF. To assess the total
iagnostic performance of BNP for diagnosing acute HF,
Table 2. Patient Characteristics in Patients W
Subdivided According to a Final Diagnosis of
Permanent/Paro
Atrial Fibrill
and CHF
Total number of patients 219
Demographics
Age (yrs) 77 (67–83)
Gender (female) 87 (39.7)
Medical history
Congestive heart failure 123 (56.2)
Myocardial infarction 81 (37.0)
Arterial hypertension 130 (59.4)
Diabetes mellitus 55 (25.1)
Clinical findings
Jugular vein distension 109 (49.8)
Orthopnea 144 (65.8)
Lower extremity edema 152 (69.4)
Rales 158 (72.1)
Body mass index (kg/m2) 26 (22–32)
Medication at home
ACE inhibitors 94 (42.9)
Beta-blockers 59 (26.9)
Calcium channel blockers 63 (28.8)
Digoxin 105 (47.9)
Other antiarrhythmics 39 (17.8)
Diuretics 151 (68.9)
ECG
Left bundle branch block 20 (9.1)
Right bundle branch block 23 (10.5)
QRS duration (ms) 102 (92–132
Blood values
Creatinine clearance 48 (33–68)
BNP 100 pg/ml 207 (94.5)
BNP (pg/ml) 569 (290–1,0
Values given as n (%) or median (interquartile range).
CHF  congestive heart failure; other abbreviations as inOC analyses (Fig. 2) revealed an area under the curve of c.84 (interquartile range 0.78 to 0.89) and 0.91 (interquar-
ile range 0.89 to 0.93) for patients with permanent/
aroxysmal AF and patients without AF, respectively.
here was no significant difference in ROC area under the
urve for patients with current (n  158: 0.80 [95%
onfidence interval 0.69 to 0.90]) versus those with a history
f but no current AF (n  134: 0.86 [95% confidence
nterval 0.80 to 0.93]). Neither was there any significant
ifference in the BNP value between patients with current
ersus those with a history of but no current AF (377.8
interquartile range 113.7 to 912.3] vs. 465.3 [interquartile
ange 199.5 to 910.1], p  0.189) (Fig. 3).
ISCUSSION
ur study demonstrates that in dyspneic patients without
F, permanent/paroxysmal AF is associated with increased
irculating BNP levels. This pattern was not evident in
atients with a final diagnosis of HF. Although the overall
iagnostic performance of BNP for HF tended to be lower
n patients with AF than in those without, BNP performed
ell in both groups. Our data also demonstrate that the
ermanent/Paroxysmal Atrial Fibrillation
e Congestive Heart Failure or Not
al Permanent/Paroxysmal
Atrial Fibrillation
and No CHF
p
Value
73
74 (69–79) 0.113
26 (35.6) 0.531
13 (17.8) 0.001
13 (17.8) 0.001
35 (47.9) 0.049
19 (26.0) 0.893
13 (17.8) 0.001
28 (38.4) 0.001
26 (35.6) 0.001
28 (38.4) 0.001
25 (22–30) 0.258
23 (31.5) 0.092
15 (20.5) 0.292
24 (32.9) 0.460
23 (31.5) 0.019
8 (11.0) 0.169
33 (45.2) 0.001
7 (9.6) 0.907
6 (8.2) 0.565
90 (81–114) 0.007
59 (44–80) 0.004
44 (60.3) 0.001
119 (69–244) 0.001
e 2.ith P
Acut
xysm
ation
)
31)onventional cutoff value of 100 pg/ml was associated with
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BNP and AF September 6, 2005:838–44markedly lower specificity and positive likelihood ratio in
atients with AF than in those without, suggesting that a
igher diagnostic threshold should be used to diagnose HF
n patients with AF.
The most widely accepted indication for BNP measure-
ent in clinical practice is for the emergency diagnosis of
F in patients presenting with acute dyspnea. The first
able 3. Diagnostic Performance of Different BNP Cutoff Value
Patients’ BNP Sensitivity Specificity
Positiv
Predict
Value
trial fibrillation
50 pg/ml 98.6 20.5 78.8
100 pg/ml 94.5 39.7 82.5
200 pg/ml 85.4 72.6 90.3
300 pg/ml 74.4 79.5 91.6
400 pg/ml 64.4 86.3 93.4
500 pg/ml 55.3 87.7 93.1
600 pg/ml 47.0 89.0 92.8
700 pg/ml 42.5 89.0 92.1
800 pg/ml 35.6 93.2 94.0
o atrial fibrillation
50 pg/ml 96.4 65.0 63.8
100 pg/ml 88.5 78.7 72.7
200 pg/ml 78.9 88.2 81.1
300 pg/ml 70.8 91.1 83.6
400 pg/ml 61.6 92.8 84.6
500 pg/ml 55.1 93.9 85.4
600 pg/ml 49.9 94.7 85.7
700 pg/ml 47.2 96.0 88.2
800 pg/ml 47.0 96.4 88.2
NP  B-type natriuretic peptide.
igure 2. Receiver-operating characteristic curve for various cutoff levels of
-type natriuretic peptide in differentiating between dyspnea due to acute
eart failure and dyspnea due to other causes in patients with and without
trial fibrillation. The area under the curve was 0.84 (95% confidences
nterval 0.78 to 0.89) and 0.91 (95% confidence interval 0.89 to 0.93) for
hose with and without atrial fibrillation, respectively.tudy suggesting that BNP measurement could prove useful
n this setting was published 10 years ago (20). However,
linical use of this test was limited until the publication of
he Breathing Not Properly Multinational Study, a multi-
enter diagnostic test evaluation study that included 1,586
cutely dyspneic patients, which documented that measure-
ent of BNP on admission provides valuable diagnostic
nformation in this patient group (16,17) complementary
nd superior to clinical evaluation. However, even in the
bsence of left-sided HF, a number of other factors,
ncluding advanced patient age and female gender (21–23);
ecreased body mass index (24 –26); decreased renal
unction (9,27); left ventricular hypertrophy (28); history
f myocardial infarction and ongoing cardiac ischemia
29 –33), pulmonary embolism (34); chronic right ven-
ricular failure (35); and cardiac arrhythmias, including
F (12,36); have previously been associated with elevated
NP levels. There have been concerns that the presence
f one or more of these factors could obscure the
ssociation between BNP and HF, thereby reducing
iagnostic performance.
Our findings show that AF is associated with increased
NP levels in patients without HF, but this pattern was not
bserved in dyspneic patients with HF, probably because
entricular dysfunction is associated with greater BNP
elease than is AF. Whereas the ventricular myocardium is
elieved to be the major source of circulating BNP in HF,
he cardiac atria, containing much less muscle mass than the
eft ventricle, may be the predominant source of BNP in
F. Accordingly, increased pro-BNP messenger ribonucleic
cid expression in right atrial appendages has been docu-
ented in patients with persistent AF (37). Moreover,
he Diagnosis of Acute Heart Failure
Negative
Predictive
Value Accuracy
Positive
Likelihood
Ratio
Negative
Likelihood
Ratio
83.3 79.1 1.2 0.07
70.7 80.8 1.6 0.1
62.4 82.2 3.1 0.2
50.9 75.7 3.6 0.3
44.7 69.9 4.7 0.4
39.5 63.4 4.5 0.5
35.9 57.5 4.3 0.6
34.0 54.1 3.9 0.6
32.5 50.0 5.2 0.7
96.6 77.3 2.8 0.06
91.5 82.5 4.2 0.1
86.7 84.5 6.7 0.2
82.9 83.1 7.9 0.3
79.0 80.6 8.5 0.4
76.5 78.8 9.1 0.5
74.7 77.2 9.4 0.5
73.9 76.9 11.7 0.6
72.2 75.2 11.7 0.6s in t
e
iveelective catheterization of the coronary sinus and the
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September 6, 2005:838–44 BNP and AFnterior interventricular vein in patients with lone fibrilla-
ion has suggested that BNP is produced in the atrium in
F (38). Even in patients without AF, BNP levels appear to
e higher in atrial tissue than ventricular tissue on a gram
er wet weight basis (3).
The diagnostic performance of BNP tended to be lower
n patients with AF than in those without. This can
robably be ascribed to the higher levels of BNP in patients
ith AF and no HF than in those without AF and no HF.
he difference was modest and the overall diagnostic
erformance, as assessed by ROC analyses, was not mark-
dly different between patients with and without AF.
ooking at the effect of different specific thresholds, how-
ver, it seemed that a cutoff of 200 pg/ml resulted in a
arked improvement in specificity and positive likelihood
atio compared with the conventional cutoff of 100 pg/ml,
ith little loss of sensitivity in patients with AF. Accord-
ngly, ROC analysis suggested that 262 pg/ml represented
he optimal tradeoff between sensitivity and specificity in
atients with AF (optimal defined here as closest to the
pper left corner), which was higher than for patients
ithout AF (162 pg/ml). Clinicians are therefore probably
est advised to interpret mildly elevated BNP tests with
aution, and additional, more specific investigations may be
equired.
tudy limitations. The interpretation of permanent/
aroxysmal AF was based on previous medical records or
nformation from the patient, and misclassifications possibly
xist. These might have led to an underestimation of the
resence of permanent/paroxysmal AF. The fact that there
as no objective “gold standard” for the diagnosis of acute
F is another important limitation.
onclusions. We have found that in patients without, but
ot in those with HF, the presence of AF was associated
igure 3. B-type natriuretic peptide levels in patients with atrial fibrillation
n the electrocardiogram (ECG) on admission (n  158), and in patients
ith a medical history of atrial fibrillation but sinus rhythm on the ECG
n admission (n  134) (p  0.189). B-type natriuretic peptide (BNP)
evels are plotted on a log scale. The boxes represent the 25th, 50th, and
5th percentiles, and the whiskers indicate the 10th and 90th percentiles.ith higher circulating BNP levels, suggesting that a higheriagnostic threshold should be used in patients with AF.
oreover, the total diagnostic performance of BNP in the
iagnosis of acute HF was somewhat lower for patients with
F compared to those without, but BNP still performed
ell in both groups.
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